Benjamin Levy, MD

Articles

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Updates in Treatment of HER2 Mutant NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Clinical Management of NTRK+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Clinical Management of RET+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

RET Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ROS1+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

ROS1 Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ALK+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

ALK Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Testing for Gene Alterations and Protein Expression in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 11th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 11th 2021

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.

<1 2 3